生物制药未来：全链路 AI 转型驱动.docxVIP

Executive

Perspectives

TheFutureofBiopharma

withE2EAITransformation

Biopharma

January2026

Introduction

WemeetoftenwithCEOstodiscussAI---atopicthatisbothcaptivatingandrapidly

changing.Afterworkingwithover2,000clientsinthepast2+years,wearesharingourmostrecentlearninginanewseriesdesignedtohelpCEOsnavigateAI.Withmostsectorsgoingthroughmajorshifts,thefocusin2025isonhowtoleverageAItofullytransformorganizationsandcreatenewsourcesofcompetitive

advantage.

Inthisedition,wediscussthefutureofBiopharmaandtheroleAIwillplayinturbocharginggrowth.WeaddresskeyquestionsonthemindsofBiopharmaexecutives:

?HowcanAIreshapecompetitivenessinBiopharma?

?WhatdoesitmeantooperateasanAI-firstenterpriseend-to-end?

?HowareleadingplayerscreatingvaluewithAItoday?

?WhatpragmaticstepsshouldItaketoscaleimpact?

ThisdocumentisaguideforBiopharmaexecutivestocutthroughthehypearoundAIandunderstandwhatcreatesvaluenowandinthefuture.

In

InthisBCG

ExecutivePerspective,wearticulatethevisionandvalueofthefutureofBiopharmawithAI

3

Executivesummary|ThefutureofBiopharmawithE2EAItransformation

WHY

WHYnowistherighttimetoact

?MarketpressuresrequiretransformationsacrossRD,ops,andcommercial;risingRDcostsandlongertimelinesareunsustainable;AIhasalreadyshownitcancutdiscoveryfrom4-5yearsto8monthsandacceleratetrialsby20%

?AIisnowaprovenenterpriseenabler;beyondpilots,scaleduseisdriving+23%yieldimprovementsinmanufacturing

?LeaderswhomovedecisivelywillunlockoutsizedPLimpactandredefinecompetitiveadvantage;AIadoptioninBiopharmahaspotentialtogenerate10-15%revenueuplift

WHATleadingBiopharmacompaniesaredoingtocreatevalueleveragingAI

WHATleadingBiopharma

companiesaredoingtocreatevalueleveragingAI

―RD–AI-drivenmoleculedesign,in-silico